Glaukos Corp Cash Flow Conversion Efficiency
Glaukos Corp cash flow conversion efficiency. Based on the latest financial reports, Glaukos Corp (GKOS) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.53 Million) by net assets ($670.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Glaukos Corp (2012–2025)
Cash flow conversion efficiency of Glaukos Corp from 2012 to 2025. This chart illustrates how Glaukos Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Glaukos Corp stock price today for real-time trading data and today's change.
Glaukos Corp Cash Flow Conversion Ratio Explained
Glaukos Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Glaukos Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Glaukos Corp ranked by their cash flow conversion efficiency. Also see Glaukos Corp (GKOS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Plaza S.A
SN:MALLPLAZA
|
0.010x |
|
Grupo Aeroportuario del Sureste S. A. B. de C. V
MX:ASURB
|
0.075x |
|
Henry Schein Inc
NASDAQ:HSIC
|
-0.020x |
|
Shandong Hi-speed Co Ltd
SHG:600350
|
0.028x |
|
Ternium SA ADR
NYSE:TX
|
0.013x |
|
Pegatron Corp
TW:4938
|
-0.156x |
|
MOL NA A ADR REG.S 1/2
F:MOGG
|
0.046x |
|
Berry Global Group Inc
NYSE:BERY
|
0.063x |
Annual Cash Flow Conversion Efficiency for Glaukos Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Glaukos Corp from 2012 to 2025. Review Glaukos Corp free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $656.15 Million | $-46.34 Million | -0.071x | +11.67% |
| 2024-12-31 | $766.93 Million | $-61.32 Million | -0.080x | +36.08% |
| 2023-12-31 | $461.77 Million | $-57.76 Million | -0.125x | -100.39% |
| 2022-12-31 | $530.00 Million | $-33.08 Million | -0.062x | -248.33% |
| 2021-12-31 | $587.15 Million | $24.71 Million | 0.042x | +222.18% |
| 2020-12-31 | $667.45 Million | $-22.99 Million | -0.034x | -6184.16% |
| 2019-12-31 | $673.27 Million | $-369.00K | -0.001x | -100.51% |
| 2018-12-31 | $173.86 Million | $18.86 Million | 0.109x | -41.21% |
| 2017-12-31 | $138.20 Million | $25.51 Million | 0.185x | +75.85% |
| 2016-12-31 | $117.27 Million | $12.31 Million | 0.105x | +556.64% |
| 2015-12-31 | $95.19 Million | $-2.19 Million | -0.023x | -152.04% |
| 2014-12-31 | $-160.90 Million | $-7.11 Million | 0.044x | -50.52% |
| 2013-12-31 | $-149.04 Million | $-13.30 Million | 0.089x | -96.09% |
| 2012-12-31 | $-8.95 Million | $-20.45 Million | 2.285x | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more